Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Declines By 23.3%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 4,600 shares, a drop of 23.3% from the September 15th total of 6,000 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 26,800 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BRNS. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics in the second quarter valued at $25,000. Ipswich Investment Management Co. Inc. purchased a new position in shares of Barinthus Biotherapeutics in the 2nd quarter worth about $32,000. BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics during the 1st quarter valued at about $1,292,000. DC Funds LP bought a new position in shares of Barinthus Biotherapeutics during the 1st quarter valued at about $1,528,000. Finally, Alphabet Inc. purchased a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at about $2,119,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a research note on Thursday, September 26th. Alliance Global Partners lowered their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a report on Tuesday, August 13th.

Barinthus Biotherapeutics Price Performance

NASDAQ BRNS traded up $0.03 during trading on Tuesday, reaching $1.20. The company’s stock had a trading volume of 5,802 shares, compared to its average volume of 22,958. The stock has a market capitalization of $46.84 million, a PE ratio of -0.64 and a beta of -0.53. The firm has a fifty day moving average of $1.26 and a 200 day moving average of $1.76. Barinthus Biotherapeutics has a one year low of $1.11 and a one year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). Research analysts expect that Barinthus Biotherapeutics will post -1.71 earnings per share for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.